HC Wainwright Comments on TG Therapeutics Q1 Earnings

TG Therapeutics, Inc. (NASDAQ:TGTX) – Research analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of TG Therapeutics in a research report issued on Tuesday, March 4th. HC Wainwright analyst E. White expects that the biopharmaceutical company will earn $0.28 per share for the quarter. HC Wainwright has a “Buy” rating and a $55.00 price objective on the stock. The consensus estimate for TG Therapeutics’ current full-year earnings is $0.08 per share. HC Wainwright also issued estimates for TG Therapeutics’ Q2 2025 earnings at $0.32 EPS, Q3 2025 earnings at $0.37 EPS and Q4 2025 earnings at $0.42 EPS.

A number of other equities analysts have also recently issued reports on the stock. JPMorgan Chase & Co. raised their price objective on shares of TG Therapeutics from $30.00 to $43.00 and gave the company an “overweight” rating in a research note on Monday, November 25th. StockNews.com upgraded TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $40.67.

TG Therapeutics Stock Down 1.4 %

Shares of NASDAQ TGTX opened at $35.11 on Thursday. TG Therapeutics has a 1 year low of $12.93 and a 1 year high of $36.94. The firm’s 50-day moving average is $30.86 and its 200-day moving average is $28.33. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. The firm has a market capitalization of $5.47 billion, a PE ratio of -351.06 and a beta of 2.30.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.08 by $0.07. The business had revenue of $108.19 million for the quarter, compared to analyst estimates of $100.67 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%.

Insider Transactions at TG Therapeutics

In related news, CFO Sean A. Power sold 11,337 shares of the firm’s stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $30.29, for a total transaction of $343,397.73. Following the sale, the chief financial officer now owns 670,632 shares of the company’s stock, valued at approximately $20,313,443.28. This trade represents a 1.66 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 10.50% of the company’s stock.

Institutional Investors Weigh In On TG Therapeutics

Large investors have recently modified their holdings of the business. Vermillion Wealth Management Inc. acquired a new position in shares of TG Therapeutics in the 4th quarter valued at approximately $30,000. Castleark Management LLC boosted its holdings in shares of TG Therapeutics by 25.2% in the fourth quarter. Castleark Management LLC now owns 211,370 shares of the biopharmaceutical company’s stock valued at $6,362,000 after buying an additional 42,560 shares during the period. Soleus Capital Management L.P. raised its holdings in shares of TG Therapeutics by 5.8% during the fourth quarter. Soleus Capital Management L.P. now owns 2,681,242 shares of the biopharmaceutical company’s stock worth $80,705,000 after acquiring an additional 146,702 shares during the period. Wexford Capital LP acquired a new stake in shares of TG Therapeutics during the fourth quarter worth $421,000. Finally, Redwood Investments LLC lifted its position in TG Therapeutics by 0.9% in the 4th quarter. Redwood Investments LLC now owns 94,554 shares of the biopharmaceutical company’s stock valued at $2,846,000 after acquiring an additional 886 shares in the last quarter. 58.58% of the stock is currently owned by institutional investors.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.